Develops and commercializes innovative biopharmaceutical therapies for patients with rare, often fatal diseases, focusing on pulmonary arterial hypertension, severe hereditary metabolic disorders, plasma-protein–related immunological conditions, inflammatory bowel disease, and cholestatic liver disease.